Severe Infections Treatment

Introduction to Severe Infections

• Ventilator-associated pneumonia (VAP) is a serious infection that requires prompt and effective treatment, as recommended by the Intensive Care Medicine society 1

Combination Therapy and Treatment Duration

• For severe infections, combination therapy with two active agents is considered, as recommended by the Infectious Diseases Society of America 2
• Combination therapy with two in vitro active agents is suggested for severe Acinetobacter infections, including polymyxins, aminoglycosides, tigecycline, or sulbactam combinations, with a dosing regimen of standard: 100 mg loading, then 50 mg q12h; High dose: 200 mg loading, then 100 mg q12h for tigecycline 3, 2
• Combination therapy with sulbactam and tigecycline may be an effective option, as recommended by the Journal of Microbiology, Immunology and Infection society 4
• For A. baumannii multiresistant strains, combination therapy may be more effective than monotherapy, as recommended by the Journal of Microbiology, Immunology and Infection society 4

Antibiotic Dosing Regimens

• The recommended dose of sulbactam for the treatment of VAP caused by Acinetobacter baumannii is 9-12 g/day divided into 3-4 doses, administered through prolonged infusion of 4 hours, as recommended by the Intensive Care Medicine society 1, 4
• The European Society of Intensive Care Medicine recommends carbapenems (imipenem, meropenem, doripenem) as the first-line treatment for Acinetobacter infections in areas with low carbapenem resistance, with a preferred dosing regimen of 2g every 8 hours (extended infusion recommended) for meropenem and 0.5-1 g every 6 hours for imipenem 1, 5
• The following antibiotic dosing regimens are recommended:

Treatment Duration and Assessment

• The duration of treatment should be individualized, with approximately 14 days for severe infections such as VAP 1
• Clinical response should be assessed within 48-72 hours of treatment initiation, and renal function should be monitored regularly 4

Contraindications and Risk Factors

• Tetracycline should not be used as monotherapy for serious Acinetobacter infections, even if reported as susceptible in vitro, due to the risk of resistance development 1
• Ertapenem is not recommended due to its lack of activity against Acinetobacter species 1, 5
• Risk factors for poor outcomes include prior colonization with Acinetobacter, immunosuppression, previous antimicrobial therapy, multiple invasive procedures, and mechanical ventilation, and inappropriate empiric therapy significantly increases mortality 1, 3

Guideline Recommendations and Evidence Quality

• Most recommendations for Acinetobacter treatment are based on low or very low-quality evidence, according to guidelines from the Infectious Diseases Society of America, Clinical Microbiology and Infection, and Clinical Infectious Diseases 3, 2
• The Centers for Disease Control and Prevention recommend considering combination therapy for severe infections or high bacterial loads, and verifying meropenem MIC for the isolate to guide treatment decisions 4, 1